Cargando…
Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
Immunotherapy with checkpoint blockers (ICBs), aimed at unleashing the immune response toward tumor cells, has shown a great improvement in overall patient survival compared to standard therapy, but only in a subset of patients. While a number of recent studies have significantly improved our unders...
Autores principales: | Lapuente-Santana, Óscar, Eduati, Federica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326813/ https://www.ncbi.nlm.nih.gov/pubmed/32670886 http://dx.doi.org/10.3389/fonc.2020.01027 |
Ejemplares similares
-
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
por: Lapuente-Santana, Óscar, et al.
Publicado: (2021) -
Biomarkers for immune checkpoint blockers
por: Wienand, Kirsty, et al.
Publicado: (2018) -
Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy
por: Ganjalikhani-Hakemi, Mazdak, et al.
Publicado: (2022) -
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023) -
Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)